BioArctic’s partner Eisai receives China NMPA approval for Leqembi IV maintenance dosing to treat early Alzheimer’s disease: Stockholm Tuesday, September 30, 2025, 12:00 Hrs [ ...

A new study suggests that the blood-brain barrier (BBB) remains intact in a widely used mouse model of Alzheimer’s disease.

Angel Martí, chair of Rice University's Department of Chemistry, is leading efforts to highlight chemistry's role in ...

A team of scientists at Texas Tech University Health Sciences Center (TTUHSC) has published new evidence suggesting that the brain's protective shield - known as the blood-brain barrier (BBB) - ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

New research shows fat buildup disables brain’s immune defenses in Alzheimer’s. A mouse treatment cleared plaques in just one week.

Lewy body dementia affects more than one million people in the United States. It has two forms: Dementia with Lewy bodies and ...

Mount Sinai scientists analyzed over 12,000 brain proteins, uncovering how neuron–glia communication failures drive Alzheimer ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...

The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive ...

Scientists are testing a novel blood-based method to detect Alzheimer’s disease by analyzing microvesicles that reveal how ...

Lecanemab has been approved in 50 countries and is under regulatory review in 10 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance ...